Why in news The Indian Council of Medical Research (ICMR) and Panacea Biotec Ltd. announced the initiation of the first Phase 3 clinical ...
Why in news
The Indian Council of Medical Research (ICMR) and Panacea Biotec Ltd. announced the initiation of the first Phase 3 clinical trial for a dengue vaccine in India.
The trial will evaluate the efficacy of dengue vaccine, DengiAll
DengiAll
It is India’s indigenous tetravalent dengue vaccine
Developed by Panacea Biotec.
The tetravalent dengue vaccine strain (TV003/TV005), originally developed by the National Institutes of Health, U.S., has shown promising results worldwide.
Panacea Biotec, one of three Indian companies to receive the strain, is at the most advanced stage of developing the vaccine
At present India does not have any antiviral treatment or licensed vaccine against dengue.
COMMENTS